Aclarion Partners with ATEC to Commercialize Nociscan

Aclarion executed a non-binding Letter of Intent (LOI) to form a strategic partnership with ATEC Spine. The partnership aims to include Aclarion’s Nociscan surgical decisioning technology within ATEC’s AlphaInformatiX platform to better inform spine surgery.

Uniting the structural data powered by ATEC’s AlphaInformatiX with the biomarker data that enables Aclarion’s Nociscan solution to identify each disc as painful or not will provide surgeons with data across one platform. The platform is designed to improve clinical outcomes while reducing overall procedural costs for patients with chronic back pain.

Aclarion’s proprietary decision-support tool, Nociscan, is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to highlight whether a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.

The LOI proposes a multi-step strategic partnership. Under the LOI, ATEC and Aclarion will work together to identify Key Opinion Leader surgeons to evaluate Nociscan technology. Feedback from these surgeons will inform clinical evaluations designed to assess the utility of Nociscan in conjunction with EOS imaging, the foundation of ATEC’s AlphaInformatiX platform. Assuming positive synergies, ATEC and Aclarion will co-market Nociscan in targeted markets. In exchange for select access to ATEC’s surgeon network for the evaluation and advancement of Nociscan, Aclarion will provide ATEC with certain exclusive distribution rights to include Nociscan as part of an integrated procedural solution.

Source: Aclarion, Inc.